Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Novavax Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -28.95% and a profit margin of -29.80%, with a gross margin of 154.25%. The ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.61 which represents a slight increase of $1.69 or 14.18% from the prior close of $11.92. The stock opened at $11.87 and touched a ...